JNJ-5207787 (10 μM; 15 min) suppresses [125I]PYY labeling in the lateral septum, cerebellum, ventral tegmental area, substantia nigra, hippocampus, septum, amygdala, and hypothalamus. JNJ-5207787 (0.01, 0.1, 1, 10 μM) has antagonistic properties and suppresses the PYY-stimulated [35S]GTPγS binding to basal level with a p IC50 corr of 7.20 [1].

JNJ-5207787 (i.p.; 30 mg/kg) penetrates the brain (Cmax=1351 ng/ml at 30 min) and occupies Y2 receptor binding sites[1].